Stephan Stern

Company: Frederick National Laboratory for Cancer Research

Job title: Director, Research & Development, Nanotechnology Characterization Lab, Cancer Research Technology Program

Bio:

Dr. Stern is Laboratory Director of Research and Development and Head of the pharmacology and toxicology section of the Nanotechnology Characterization Laboratory. In this role, Dr. Stern leads new research initiatives and oversees application to the NCL Assay Cascade program. Dr. Stern is also involved in the design and implementation of pharmacology and toxicology studies used to characterize nanoparticle disposition and assess nanoparticle biocompatibility, as well as NCL drug formulation efforts. Data generated from these studies support formulation optimization and translation, including investigational new drug regulatory filings. Additional responsibilities include representation of NCL at local and national nanotechnology meetings, and the education of study personnel regarding nanoparticle safety issues.

Seminars:

Novel Bioanalytical Methods to Determine LNP Biodistribution & Stability 11:30 am

Determination of lipid nanoparticle (LNP) pharmacokinetics is important for understanding targeted and off-target distribution, but has been limited by the lack of generally applicable, bioanalytical methods We have recently developed a novel bioanalytical method to quantify DSPC, a common lipid component lipidic formulations, including LNPs This presentation will showcase DSPC pharmacokinetic data for multiple lipidic…Read more

day: Conference Day Two